Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tesaro licenses exclusive rights to Merck's cancer therapy niraparib

Executive Summary

Cancer drug start-up Tesaro Inc. has in-licensed its third development program, this time from Merck & Co. Inc. and its Merck Sharp & Dohme Ltd. division. Tesaro gets exclusive worldwide rights to develop, manufacture, and sell Merck’s Phase I niraparib and back-up compound MK2512.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Reverse Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register